← FDA DRUG APPROVALS

FDA ANDA · ANDA091228

PREGABALIN

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA091228
TYPE
ANDA
ORIGINAL APPROVAL
2019-09-20
LATEST ACTION
2019-09-20
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

PREGABALINDiscontinued
PREGABALIN 300MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 200MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 100MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 50MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 225MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 150MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 75MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 25MG · CAPSULE · ORAL

Approval history

2019-09-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →